SWMAF yields 100.50% · JNJ yields 2.13%● Live data
📍 SWMAF pulled ahead of the other in Year 1
Combined, SWMAF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SWMAF + JNJ for your $10,000?
Swedish Match AB (publ) develops, manufactures, markets, and sells snus and moist snuff, lights, and other tobacco products in Scandinavia, the United States, and internationally. The company operates through Smokefree, Cigars, and Lights segments. It provides snus and pouch products, nicotine pouches, nicotine free products, and moist snuff under the General, Göteborgs Rapé, Kaliber, Kronan, Ettan, Grov, Catch, G.3, The Lab, Nick & Johnny, Thunder, VOLT, Swave, ZYN, G.4, Onico, Qvitt, Longhorn, and Timber Wolf brand names. The company offers chewing tobacco products under the Red Man and Big Duke brand names; chew bags under the Thunder and Göteborgs Rapé brands; and tobacco bits under the Oliver Twist brand name. In addition, it provides cigars under the Garcia y Vega, Game by Garcia y Vega, 1882, White Owl, and Jackpot brands; matches under the Solstickan, Nitedals, Fiat Lux, and Redheads brand names; lighters under the Cricket brand; and complementary products, such as razors, batteries, and light bulbs under the Fiat Lux brand name. Further, the company distributes third party tobacco products. It markets its products through convenience stores, tobacconists, gasoline stations, supermarkets, bars, restaurants, airports, and ferries, as well as e-commerce and own stores. The company was founded in 1915 and is headquartered in Stockholm, Sweden.
Full SWMAF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.